Home » Newsletters » BioWorld Science

BioWorld Science

March 18, 2016

View Archived Issues

Study results support every-other-month dosing of gerilimzumab for rheumatoid arthritis

Genentech advances on KDM5 inhibitor program

Genetic pathways linked to postpartum psychosis identified

Orphan drug designation granted in Japan for tocilizumab in systemic scleroderma

FDA grants priority review to SequestOx NDA

Inovio and Wistar Institute sign collaborative research agreements

Adjunctive sertraline shows efficacy in treatment of HIV-associated cryptococcal meningitis

EMA approves centralized review of Pulmaquin

Biota Pharmaceuticals sells antibiotic assets to Spero Therapeutics

Reset Therapeutics announces research collaboration with Alkermes

CTxT Pty patents PRMT5 inhibitors

Axsome Therapeutics enrolls first patient in phase III study of AXS-05

Pierre Fabre Medicament describes FLT3 and JAK inhibitors

Vanderbilt University discloses CHD1 expression enhancers

Eisai develops mGlu2 receptor antagonists

Boehringer Ingelheim Pharma presents Mdm2 inhibitors

Autotoxin inhibitor GLPG-1690

Halozyme initiates phase III trial of PEGPH-20 in pancreatic cancer

NIAID funding to advance development of heat stable ricin toxin vaccine RiVax

GATA3 plays a role in differentiating malignant pheochromocytoma from adrenal cortical carcinoma

Repurposing metformin into an antitumor therapeutic option

Grant supports work at Children's Hospital Los Angeles on cellular therapy for enteric neuropathies

Kalytera partners with Ramot for osteogenesis imperfecta treatment research

Aerie updates safety data for Rhopressa QD

Results from pilot phase II trial of MBX-8025 for homozygous familial hypercholesterolemia

Repros Therapeutics begins European approval process for enclomiphene

University of Queensland and AngioStem sign stem cell research licensing agreement

FDA's OND grants Fabre-Kramer's appeal for Travivo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...